Eli Lilly subsidiary secures exclusive rights to veterinary drug
Insight Weekly: Loan-to-deposit ratio rises; inventory turnovers ebb; miners add female leaders
Debt Ceiling Debate: IR Teams Should Prepare for Potential Market Downturns
Insight Weekly: Sustainable bonds face hurdles; bad loans among landlords; AI investments up
Insight Weekly: Bank oversight steps up; auto insurers’ dismal year; VC investment slumps
Elanco US Inc. secured the exclusive global rights to Jaguar Animal Health Inc.'s Canalevia for the potential treatment of acute and chemotherapy-induced diarrhea in dogs.
The Eli Lilly & Co. subsidiary will pay Jaguar Animal $1.5 million in up-front payment and another $61 million tied to the completion of certain milestones for the drug, which is currently under investigation.
